Introduction: Nail psoriasis occurs in 50%-70% of patients with psoriasis (PsO) and 60%- 80% of patients with psoriatic arthritis (PsA). Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has proven highly efficacious in the long-term treatment of the multiple manifestations of psoriatic disease, with a favorable safety profile. Here, we report the long-term results of post hoc analyses of clearing (ie achieving clear or almost clear) nail psoriasis from the secukinumab PsA FUTURE program, and from the PsO TRANSFIGURE study.

Methods: These post hoc descriptive analyses focused on the year 2 NAPSI (range: 0- 80) or mNAPSI (range: 0-130) #2 outcomes, defining clear or almost clear nails, in patients treated with 300 mg secukinumab in the TRANSFIGURE and the pooled FUTURE 2-5 studies. Analyses were performed based on observed data from all 10 fingernails.

Results: In the TRANSFIGURE secukinumab 300 mg treatment group (n ¼ 66), the mean baseline NAPSI was 45.5; at year 2, 25.0% of patients had achieved a NAPSI #2. In the pooled FUTURE secukinumab 300 mg treatment group (n ¼ 220), the mean baseline mNAPSI was 20.9; at year 2, 66.7% of patients had achieved a mNAPSI #2.

Conclusions: Secukinumab demonstrated a high level of efficacy in clearing nail PsO, in patients with or without concomitant PsA, even in patients with severe baseline nail involvement seen in the TRANSFIGURE study.